John Quisel, Disc Medicine CEO
April 1, 2024 11:02 AM EDT
R&D

Disc Med­i­cine blames 'out­sized' place­bo re­sponse on mixed Phase 2 da­ta in rare blood dis­or­der

Amber Tong

De­spite dri­ving re­duc­tions in a key bio­mark­er, Disc Med­i­cine’s drug for a rare blood dis­or­der flunked on ef­fi­ca­cy in a Phase 2 study. The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

A service from the Financial Times